-
Clinical Trials & Development3 weeks agoBristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary Endpoint
In the trial, admilparant at the 60 mg dose demonstrated a statistically significant benefit in absolute change in forced vital capacity (FVC) from baseline to Week...
-
Clinical Trials & Development3 weeks agoBMS’ Phase 3 win for lung drug clouded by high-dose miss
A low-dose win could derisk a regulatory pathway for BMS’ LPA1 antagonist in idiopathic pulmonary fibrosis after a recently reported patient death, but a miss at...
-
Clinical Trials & Development3 weeks agoBMS’ $4.1B RayzeBio bet delivers Phase 3 radiopharma win
The centerpiece of Bristol Myers Squibb’s 2024 RayzeBio buy has read out, hitting the primary endpoint in a late-stage tumor trial.
-
Clinical Trials & Development3 weeks ago
Encaleret Increased Bone Turnover and Improved Participant-Reported Symptoms in the Phase 3 CALIBRATE Trial in ADH1
PALO ALTO, Calif., Oct. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing...
-
Clinical Trials & Development3 weeks ago
Efzimfotase Alfa Showed Numerical Improvement in Six-Minute Walk Test Achieving Mean Difference of 17.05 Metres vs Placebo in Treatment-Naïve Adolescents and Adults with Hypophosphatasia at Week 25 in HICKORY Phase III Trial
11 October 2026 -- Results from the HICKORY Phase III trial showed that efzimfotase alfa (ALXN1850), an investigational enzyme replacement therapy, did not achieve statistical significance...
-
Clinical Trials & Development3 weeks ago
Merck Presents One-Year Results from the Pivotal Phase 2b/3 BRUNELLO Study Evaluating Remigromig, a Tri-Specific Agonist of the Wingless-Related Integration Site (Wnt) Pathway, in Adults with Diabetic Macular Edema
RAHWAY, N.J.--(BUSINESS WIRE) October 10, 2026 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of...
-
Clinical Trials & Development3 weeks ago
Roche Presents New Phase III One-Year Data for Vamikibart in Uveitic Macular Edema
Basel, 10 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today new one-year data from the Phase III MEERKAT and SANDCAT studies evaluating investigational...
-
Clinical Trials & Development3 weeks agoPhase 1 Investigational New Drug (IND) Navigator
The Phase 1 IND Navigator provides the tools, guidances, and regulatory expertise you need to prepare and submit an successful Investigational New Drug (IND) application.
-
Clinical Trials & Development3 weeks agoPhase 1 IND Frequently Asked Questions
Answers to frequently asked questions related to Phase 1 INDs
-
Clinical Trials & Development3 weeks agoSTAT+: Pharmalittle: We’re reading about a setback for Argenx, Lilly suits over copycat versions of an obesity drug, and more
The FDA flagged a potential safety signal after four patient deaths in a trial testing a schizophrenia drug, Argenx faces an unusual setback, and more pharma...
LncRNA SBF2-AS1 Worsens Heart Injury After Attack via miR-149-5p/PHLPP2 Axis
Stigmatizing language found in over half of primary care patient records
Research report: The Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Iclepertin (BI 425809): Results from Two Phase I Open-Label, Non-randomised, Single Dose, Parallel Design Studies
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
